ストックスクリーナーアプリを入手
7.47
0.40%
0.03
アフターアワーズ：
7.50
0.03
+0.40%
前日終値:
$7.44
開ける：
$7.5
24時間の取引高:
9.93M
Relative Volume:
5.69
時価総額：
$2.75B
収益：
$9.47B
当期純損益:
$-178.00M
株価収益率:
-15.56
EPS:
-0.48
ネットキャッシュフロー:
$1.01B
1週間 パフォーマンス:
-0.13%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
-1.71%
1年 パフォーマンス:
-8.34%
1日の値動き範囲:
$7.42
$7.72
1週間の範囲:
$7.39
$7.72
52週間の値動き範囲:
$3.96
$11.46
Bausch Health Companies Inc Stock (BHC) Company Profile
名前
Bausch Health Companies Inc
セクター
電話
514-744-6792
住所
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
BHC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
7.47 | 2.75B | 9.47B | -178.00M | 1.01B | -0.48 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-02 | ダウングレード | Piper Sandler | Neutral → Underweight |
| 2024-07-10 | 開始されました | Raymond James | Mkt Perform |
| 2023-09-20 | アップグレード | Jefferies | Hold → Buy |
| 2023-06-16 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | ダウングレード | Truist | Buy → Hold |
| 2022-07-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-06-13 | 再開されました | JP Morgan | Overweight |
| 2021-03-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-02-17 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-24 | 開始されました | Citigroup | Buy |
| 2020-04-02 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-02 | 開始されました | Goldman | Neutral |
| 2019-10-25 | 開始されました | Cowen | Outperform |
| 2019-09-12 | 開始されました | Guggenheim | Buy |
| 2019-08-15 | アップグレード | TD Securities | Hold → Buy |
| 2019-07-19 | 開始されました | Wolfe Research | Outperform |
| 2019-06-11 | 再開されました | Barclays | Overweight |
| 2019-05-13 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-01-02 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | アップグレード | Piper Jaffray | Underweight → Neutral |
すべてを表示
Bausch Health Companies Inc (BHC) 最新ニュース
Xifaxan selected for CMS drug price talks in 2027 - MSN
Bausch Health Companies (NYSE:BHC) Sees Strong Trading VolumeHere's Why - MarketBeat
Bausch Health acknowledges XIFAXAN selection for Medicare Negotiation Program - MSN
Xifaxan selected for CMS drug price talks in 2027 By Investing.com - Investing.com South Africa
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales - MSN
Bausch Health Statement on Selection of XIFAXAN(R)?(rifaximin) for Inflation Reduction Act's Medicare Negotiation Program - WICZ
Bausch Health’s XIFAXAN Selected for Medicare Price Negotiation - TipRanks
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program - Yahoo Finance
Topical Drugs Market Trends Analysis Report 2025-2030, with - GlobeNewswire
Topical Drugs Market Trends Analysis Report 2025-2030, with Profiles of Bayer, Cipla, GSK, Novartis, Bausch Health Companies, Hisamitsu Pharmaceuticals, Merck, Glenmark Pharmaceuticals & MedPharm - Yahoo Finance
FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - MSN
Innovations in Scar Treatment Market: What to Expect by 2031 | Bausch Health Companies Inc., Candela Medical - EIN News
Bausch Health Companies Inc. (NYSE:BHC) Receives $7.75 Average PT from Analysts - MarketBeat
Deal Watch: Bausch Companies Set Hectic Pace At J.P. Morgan With Five Deals - News & Insights
Actinic Keratosis Market Investment Opportunities: A Guide to 2031 | Almirall, S.A, Bausch Health Companies Inc. - openPR
Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America - The Manila Times
George Medicines signs exclusive licensing agreement with - GlobeNewswire
Barclays PLC Cuts Position in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Is Bausch Health Companies (BHC) the Best Medical Stock to Buy Under $20? - Yahoo Finance
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Bausch Health Companies (TSE:BHC) Trading Up 3%Here's Why - MarketBeat
Here's Why Bausch Health (BHC) is a Strong Momentum Stock - Yahoo Finance
Myopia And Presbyopia Treatment Market Future Business - openPR
Botanical and Plant-Derived Drugs Market to Grow by USD 18.66 Billion (2025-2029), Driven by Government Initiatives and AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Bausch Health Companies Inc (BHC-T) QuotePress Release - The Globe and Mail
124,534 Shares in Bausch Health Companies Inc. (NYSE:BHC) Bought by Range Financial Group LLC - MarketBeat
Atopic Dermatitis Pipeline Review 2024: Clinical Trials Update and Market Impact by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan PLC, Bausch Health - Barchart
Scar Treatment Market Overall Study Report 2025-2032 | Bausch - openPR
Geode Capital Management LLC Increases Holdings in Bausch Health Companies Inc. (NYSE:BHC) - MarketBeat
Non-surgical Skin Tightening Market Report 2024-2029, with - GlobeNewswire
$2.5+ Bn Body Contouring Treatments MarketsGlobal Analysis and Forecasts to 2029 with AbbVie, Inmode), Bausch Health, Cynosure Lutronic, and Sisram Medical Leading - GlobeNewswire
Face Treatment Market Key Players AnalysisLutron, Bausch - openPR
BAUSCH HEALTH COMPANIES INC. DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bausch Health Companies Inc. (NYSE:BHC) - AccessWire
Bausch Health Companies (BHC) Shares Cross Above 200 DMA - Nasdaq
Bausch Health Companies Inc.'s (NYSE:BHC) Path To Profitability - Simply Wall St
T-cell Lymphoma Market Key Players Analysis4SC AG, Acrotech - openPR
Periodontal Disease Treatment Market Dynamics and Key Trends: - openPR
Bausch Health Companies Inc. (NYSE:BHC) Receives $7.75 Consensus Target Price from Analysts - MarketBeat
Bausch + Lomb confirms potential sale is 'one of several options being explored' - MSN
Zacks Research Issues Optimistic Outlook for BHC Earnings - MarketBeat
FY2024 EPS Estimates for TSE:BHC Raised by Analyst - MarketBeat
Zacks Research Issues Optimistic Forecast for BHC Earnings - MarketBeat
Is Bausch Health Companies (BHC) Among Billionaire Paul Singer’s Top Long-Term Stock Picks? - Yahoo Finance
Bausch Health Companies Inc. (NYSE:BHC) Stock Position Reduced by Franklin Resources Inc. - MarketBeat
Bausch Health's SWOT analysis: debt woes cloud strong q3 for diverse pharma stock - Investing.com
Canada: Bausch Health responds to rumours of potential sale of Bausch + Lomb - Investors in Healthcare
Bausch Health Companies Inc. (NYSE:BHC) Short Interest Up 9.9% in November - MarketBeat
Bausch + Lomb responds to rumors of a potential sale - The Pharma Letter
Bausch Health tanks 23.3% on unconfirmed report of bankruptcy filing - MSN
Bausch And Lomb Says Potential Sale In The Works - Law360
Bausch Health Companies Inc (BHC) 財務データ
収益
当期純利益
現金流量
EPS
2.14%
大文字化:
|
ボリューム (24 時間):